Karaburun, M. C. Et Al. 2024. Grade Heterogeneity in High-Grade Urothelial Carcinomas: Does It Have an Impact on the Survival of Patients With Intermediate/High-Risk Nonmuscle-Invasive Bladder Cancer Who Received Adequate Adjuvant Bacillus Calmette-Guérin Therapy?. The Journal of urology , vol.212, no.1 , 104-113.

Karaburun, M. C., Kuz, E. D., Akpınar, Ç., Obaid, K., Göğüş, C., KİREMİTCİ, S., ... ENNELİ, D.(2024). Grade Heterogeneity in High-Grade Urothelial Carcinomas: Does It Have an Impact on the Survival of Patients With Intermediate/High-Risk Nonmuscle-Invasive Bladder Cancer Who Received Adequate Adjuvant Bacillus Calmette-Guérin Therapy?. The Journal of urology , vol.212, no.1, 104-113.

Karaburun, MURAT Et Al. "Grade Heterogeneity in High-Grade Urothelial Carcinomas: Does It Have an Impact on the Survival of Patients With Intermediate/High-Risk Nonmuscle-Invasive Bladder Cancer Who Received Adequate Adjuvant Bacillus Calmette-Guérin Therapy?," The Journal of urology , vol.212, no.1, 104-113, 2024

Karaburun, MURAT C. Et Al. "Grade Heterogeneity in High-Grade Urothelial Carcinomas: Does It Have an Impact on the Survival of Patients With Intermediate/High-Risk Nonmuscle-Invasive Bladder Cancer Who Received Adequate Adjuvant Bacillus Calmette-Guérin Therapy?." The Journal of urology , vol.212, no.1, pp.104-113, 2024

Karaburun, M. C. Et Al. (2024) . "Grade Heterogeneity in High-Grade Urothelial Carcinomas: Does It Have an Impact on the Survival of Patients With Intermediate/High-Risk Nonmuscle-Invasive Bladder Cancer Who Received Adequate Adjuvant Bacillus Calmette-Guérin Therapy?." The Journal of urology , vol.212, no.1, pp.104-113.

@article{article, author={MURAT CAN KARABURUN Et Al. }, title={Grade Heterogeneity in High-Grade Urothelial Carcinomas: Does It Have an Impact on the Survival of Patients With Intermediate/High-Risk Nonmuscle-Invasive Bladder Cancer Who Received Adequate Adjuvant Bacillus Calmette-Guérin Therapy?}, journal={The Journal of urology}, year=2024, pages={104-113} }